Abstract
Mycoplasma pneumoniae pneumonia (MPP) is a common type of pneumonia among school-aged children and adolescents. Jinzhen Oral Liquid (JZOL) and Azithromycin (AZ) are commonly used treatment options in traditional Chinese medicine (TCM) and Western medicine, respectively. There are several clinical and basic research reports on their solo effect against MPP, enabling their combined treatment to become possible. However, the mechanisms and specific pharmacodynamics of their combined therapy remain unclear. In this study, we conducted a mechanistic analysis of the combination of JZOL and AZ based on network target, elucidating their modular network regulatory mechanisms. The modular mechanisms involve four modules, including hormone response, cell differentiation and migration, signal transduction, oxygen and hypoxia response, centered by TNF signaling pathway-mediated regulation. Under the instruction of computational analysis, we conducted a randomized, double-blind, three-armed, parallel-controlled, multicenter clinical study of different doses of JZOL combined with AZ for the treatment of MPP in children. At the study endpoint, the median time to clinical recovery showed statistically significant differences, which were also observed between groups for time to complete fever remission, time to relief of cough/phlegm, effective rate of chest X-ray improvement, and rate of healing of TCM symptoms. During the treatment period, there were no statistically significant differences in the rates of adverse events, serious adverse events, or adverse reactions between the groups. Different doses of JZOL combined with AZ in the treatment of MPP in children have shown the effects of shortening the course of the disease, relieving the symptoms, and improving the prognosis. The research program composed of computational prediction and clinical trials can significantly accelerate the research and development process and identify more effective treatment with good safety, which is worthy of clinical promotion.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
The research has been registered with the China Clinical Trials Registry (registration number: ChiCTR1800019007) and has passed the ethical review of the leading unit's medical ethics committee (ethics approval number: TYLL2017[Y]020).
Funding Statement
This work was supported by the Jiangsu Provincial Department of Science and Technology-Basic Research Program Natural Science Fund - Frontier Leading Technology Basic Research Special Project "Research on the efficacy substance of traditional Chinese medicine compound based on the combination of disease and syndrome" (SBK2023050003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The research has been registered with the China Clinical Trials Registry (registration number: ChiCTR1800019007) and has been approved by the Medical Ethics Committee of the First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, which is the ethical review of the leading unit's medical ethics committee (ethics approval number: TYLL2017[Y]020).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations
- ADR
- adverse drug reactions
- AE
- adverse event
- AZ
- azithromycin
- CI
- confidence interval
- FAS
- full analysis set
- JZOL
- Jinzhen Oral Liquid
- MP
- Mycoplasma pneumoniae
- MPP
- Mycoplasma pneumoniae pneumonia
- PPS
- per protocol set
- RMPP
- refractory M. pneumoniae pneumonia
- SAE
- serious adverse event
- SMPP
- severe Mycoplasma pneumoniae pneumonia
- SS
- safety set
- TCM
- traditional Chinese medicine
